Recombinant human erythropoietin (rHuEPO) is an effective treatment for anaemia but concerns that it causes disease progression in cancer patients by activation of EPO receptors (EPOR) in tumour tissue have been controversial and have restricted its clinical use. Initial clinical studies were flawed because they used polyclonal antibodies, later shown to lack specificity for EPOR. Moreover, multiple isoforms of EPOR caused by differential splicing have been reported in cancer cell lines at the mRNA level but investigations of these variants and their potential impact on tumour progression, have been hampered by lack of suitable antibodies. The EpoCan consortium seeks to promote improved pathological testing of EPOR, leading to safer clinical use of rHuEPO, by producing well characterized EPOR antibodies. Using novel genetic and traditional peptide immunization protocols, we have produced mouse and rat monoclonal antibodies, and show that several of these specifically recognize EPOR by Western blot, immunoprecipitation, immunofluorescence, flow cytometry and immunohistochemistry in cell lines and clinical material. Widespread availability of these antibodies should enable the research community to gain a better understanding of the role of EPOR in cancer, and eventually to distinguish patients who can be treated safely by rHuEPO from those at increased risk from treatment.
*The work represents the efforts of the European consortium called EpoCan that is financed until September 2014 by the FP7 call.
Summary
Recombinant human erythropoietin (rHuEPO) is an effective treatment for anaemia but concerns that it causes disease progression in cancer patients by activation of EPO receptors (EPOR) in tumour tissue have been controversial and have restricted its clinical use. Initial clinical studies were flawed because they used polyclonal antibodies, later shown to lack specificity for EPOR. Moreover, multiple isoforms of EPOR caused by differential splicing have been reported in cancer cell lines at the mRNA level but investigations of these variants and their potential impact on tumour progression, have been hampered by lack of suitable antibodies. The EpoCan consortium seeks to promote improved pathological testing of EPOR, leading to safer clinical use of rHuEPO, by producing well characterized EPOR antibodies. Using novel genetic and traditional peptide immunization protocols, we have produced mouse and rat monoclonal antibodies, and show that several of these specifically recognize EPOR by Western blot, immunoprecipitation, immunofluorescence, flow cytometry and immunohistochemistry in cell lines and clinical material. Widespread availability of these antibodies should enable the research community to gain a better understanding of the role of EPOR in cancer, and eventually to distinguish patients who can be treated safely by rHuEPO from those at increased risk from treatment.
Anaemia is an independent prognostic factor for poor survival in cancer patients (Caro et al, 2001) , but the use of recombinant human erythropoietin (rHuEPO) to treat these patients is controversial due to concerns about patient safety arising from Phase III clinical trials showing more rapid cancer progression and reduced survival in subjects randomized to rHuEPO (Henke et al, 2003; Leyland-Jones et al, 2005; Miller et al, 2009) . Consequently there has been a marked decline in the use of rHuEPO since 2007 (Hill et al, 2012) . Clearly, the benefits of EPO treatment must be carefully balanced against the risk of enhanced cancer progression for each patient.
Erythropoietin functions by binding to its receptor (EPOR) on the surface membrane of erythroid progenitors and activating JAK2/STAT5 signalling pathways (Jelkmann, 2010; Wenger & Kurtz, 2011) . There is now evidence that growth factor receptor-mediated cell signalling pathways can overlap in cancer cells. In a landmark study, Liang et al (2010) found that EPOR is co-expressed with human epidermal growth factor receptor-2 (HER2, also known as ERBB2) in breast cancer cell lines and tumour specimens. rHuEPO administered to patients antagonized trastuzumab treatment and resulted in shorter progression-free and overall survival in patients with HER2positive metastatic breast cancer (Liang et al, 2010) .
Erythropoietin has pleiotropic actions and EPOR is expressed outside the haematopoietic compartment (Lappin et al, 2002; Ghezzi et al, 2010; Vogel & Gassmann, 2011) . EPOR is functionally active in endothelial cells (Anagnostou et al, 1994) and endothelial progenitor cells promoting vascular repair and endothelial regeneration (Trincavelli et al, 2013) . Moreover, EPO stimulates angiogenesis both in vitro and in vivo (Trincavelli et al, 2013) . Positive effects of EPO treatment on the immune system have been documented (Mittelman et al, 2004; Prutchi-Sagiv et al, 2006 , 2008 Katz et al, 2007; Lifshitz et al, 2010; Mausberg et al, 2011; Nairz et al, 2012; Oster et al, 2013) . EPO has thrombotic effects, at least in vitro, as it increases plasminogen activator inhibitor-1 release in HUVEC culture (Stasko et al, 2002) . Patients with end-stage renal disease on high doses of rHuEPO have high haemoglobin levels, are associated with increased risk of cardiovascular and thrombotic events, and have reduced survival (Smith et al, 2003; Provatopoulou & Ziroyiannis, 2011) . These observations support the hypothesis that supraphysiological levels of circulating EPO could lead to enhanced tumour growth, neovascularization and thrombosis in some cancer patients. Recommendations for the use of erythropoiesis-stimulating agents (ESAs) in patients with cancer have been published (Rizzo et al, 2010) .
To understand the increased risk of administering rHuEPO to patients with cancer, it is imperative to examine its effects in tumour tissue. Angiogenic factors, such as vascular endothelial growth factor A (VEGFA), platelet-derived growth factors (PDGFs), fibroblast growth factors (FGFs) and angiopoietins are often elevated in the tumour environment. PDGFBB targets perivascular cells to nascent vascular networks (Abramsson et al, 2003) and modulates tumour angiogenesis by increasing EPO production in stromal cells, leading to the induction of endothelial cell proliferation, migration, sprouting and tube formation (Xue et al, 2012) .
Contentious inferences were drawn from clinical studies that were based on immunohistochemistry (IHC) using antibodies, but later shown to lack specificity for EPOR (Elliott et al, 2006; Brown et al, 2007) . Thus, investigation of EPOR expression and function relies heavily on the availability of specific anti-EPOR antibodies.
The EU-based EpoCan project addresses safety concerns related to EPO treatment and is investigating the risks of EPO treatment using mouse models, human clinical samples and patient databases. The studies focus on the long-term effects of EPO treatment on tumour growth and incidence, the role of EPO in angiogenesis and its association with thromboembolic events in cancer and cardiovascular disease. An important initial objective was to prepare a range of highly specific monoclonal antibodies against human EPOR. To this end, a cohort of 15 EPOR mouse and rat monoclonal antibodies were produced and evaluated for different applications. Here we report on the characterization of four of these antibodies, which have proved suitable for a range of applications.
Materials and methods

Cell lines
The human cell lines used were: megakaryoblastic leukaemia cells, UT-7; acute lymphocytic leukaemia cells, REH; pre-B cells, NALM6; breast cancer cells, MDA-MB-231; human embryonic kidney cells HEK293T, and its derivative, BOSC23; and lung cancer cells, A549.
Tissue sections
Formalin-Fixed Paraffin wax-Embedded (FFPE) tissue sections and bone marrow aspirates were obtained under agreement with the Northern Ireland Biobank (Ethical approval reference NIB12-0044).
Monoclonal antibody generation by genetic immunization
Monoclonal antibodies were generated using cDNA constructs encoding the extracellular domain (ECD) of hEPOR cloned into proprietary immunization and screening vectors. Anti-tag antibodies were used to confirm expression after transient transfection of the cDNA constructs into mammalian cells, in vitro. The immunization constructs were adsorbed onto the surface of gold particles and introduced intradermally into mice and rats using a BioRad gene gun (Bio-Rad GmbH München, Germany), with several cDNA boosts, following proprietary protocols. This cDNA was taken up and translated by skin cells, whereby the protein was brought to the cell surface and finally secreted to allow an optimal immune response against the EPOR ECD. The sera were tested against both the ECD and full-length EPOR construct, the cDNA of which had been transiently transfected into mammalian cells.
Monoclonal antibody generation using synthetic peptides
The amino acid sequence of hEPOR was analysed using hydrophilicity/hydrophobicity software to identify peptide regions representing potential epitopes. In total, six peptides (h1-h6) were chosen for peptide synthesis of which five were located in the cytoplasmic domain (h2-h6) as shown for hEPOR ( Table I ). The peptides were conjugated with keyhole limpet haemocyanin for immunization and with ovalbumin for screening in peptide enzyme-linked immunosorbent assays (ELISA). Immunization was carried out intraperitoneally with one group of six peptides (h1-h6) into two cohorts of three rats. The peptides were mixed with complete Freund's adjuvant for the initial immunization, followed by several boosts with incomplete Freund's adjuvant. Following immunization of three animals per cohort, sera were tested for positivity in a peptide ELISA against ovalbumin-peptide conjugate mixes, corresponding to their immunogen mixtures. After lymphocyte fusion, the resulting hybridoma supernatants were screened against each individual ovalbumin-peptide conjugate in the same ELISA assay to identify antibodies against specific peptides.
Flow cytometry
Flow cytometry was performed essentially as described (Lifshitz et al, 2010) . Cell suspensions were analysed on a FAC-Sort flow cytometer (Becton Dickinson, Oxford, UK) and the results were analysed using WinMDI software (J.Trotter free download, http://winmdi.software.informer.com/2.8/). Anti-HA antibody (MMS-101R) was from Covance (Princeton, NJ, USA). Fluorescein isothiocyanate (FITC)-conjugated AffinityPure Goat Anti-Mouse IgG and FITC-conjugated Affinity Pure Goat Anti-Rat IgG were from Jackson Immu-noResearch Laboratories Inc. (West Grove, PA, USA).
Immunofluorescence
Cells seeded on glass cover slips (A549, MDA-MB-231, COS7 and HEK293T) or collected in a 1Á5 ml tube (UT-7) were fixed in 3% paraformaldehyde in phosphate-buffered saline (PBS) at room temperature (RT) for 30 min. After incubation in quenching buffer (0Á1% Triton, 5% fetal bovine serum, and 2% bovine serum albumin) at RT for 1 h, cells were incubated with primary antibodies diluted in quenching buffer at RT for 1 h. After washing with PBS, cells were incubated with secondary antibodies for 1 h at RT. Nuclei were stained with 2Á5 lmol/l DRAQ5(ab108410; Abcam, Cambridge, MA, USA) for 30 min at RT. Confocal fluorescent images were obtained by a TCS SP5 II confocal microscope (Leica, Wetzlar, Germany) with a 63x/1.4NA objective or a CSU10 spinning disc unit coupled to a Zeiss Axiovert 200M microscope with a 100x/1.3NA oil immersion objective. For some experiments, fusion proteins of enhanced cyan fluorescent protein (ECFP) and EPOR were made by cloning cDNA encoding for the hEPOR into the pECFP-N1 vector (Clontech, Mountain View, CA, USA) between HindIII and BamHI. A construct specific for the intracytoplasmic domain (ICD) of EPOR was generated by replacing the extracellular and transmembrane domain in the described construct by that of the epithelial growth factor receptor (EGFR) (Gross et al, 2014) . For transient transfections plasmid DNA was mixed with the transfection reagent Turbofect (Thermo Scientific, Waltham, MA, USA) according to the supplier's recommendations. The cells were incubated for 24 h with the transfection mix and subjected to immunofluorescence staining as described.
Generation of EPOR-silenced cells
Human EPOR (sc-37092-V) and control (sc-108080) shRNA lentiviral particles (Santa Cruz Biotechnology, Dallas, TX, USA) were used to generate stable transfectants in MDA-MB-231 breast cancer cells and A549 lung carcinoma cells. After lentiviral infection, infected cells were selected with puromycin (1 lg/ml) to finally generate MDA-MB-231-shE-POR, A549-shEPOR cells and their corresponding MDA-MB-231-shSCR and A549-shSCR control cells. Following puromycin selection for 11-18 d, cells were lysed in Laemmli buffer and subjected to Western blot analysis using the GM1201 antibody (see Table II ).
Western blot analysis
Cells were lysed in Laemmli buffer. Western blots were performed using 10% sodium dodecyl sulphate (SDS)-polyacrylamide gels. Membranes were incubated with a 1:1000 dilution in Tris-buffered saline (TBS)-Tween 20 (TBS-T) buffer of the indicated anti-EPOR antibody at 4°C overnight. Membranes were incubated with the corresponding secondary antibody at RT for 1 h and, finally, washed three times 
Coupling of antibodies for immunoprecipitation
For immunoprecipitation (IP), anti-EPOR antibodies or anti-HA antibodies (clone 12CA5, Abcam) were covalently coupled to protein-A agarose (Immunosorb A, Medicago, Uppsala, Sweden). Antibody (2 lg) was incubated with 5 ll Protein-A bead slurry in PBS for 1 h at RT. Beads were washed with sodium borate (0Á2 mol/l, pH 9Á0) and the antibody was cross-linked to protein-A upon addition of 40 mmol/l dimethylpimelimidate.
Cell transfection, protein extraction and IP
Plasmid encoding the N-terminal HA-tagged hEPOR was transiently transfected into HEK-293T cells with calciumphosphate (Graham & van der Eb, 1973) and harvested 48 h later. Cell extracts were prepared in IP buffer with 1% Triton X-100. Protein extracts were cleared by centrifugation (10 000 g; 20 min), protein concentration determined by BioRad-DC assay and IP performed using 40 lg extract from transfected HEK-293T cells, 750 lg of UT-7 cells or 1Á5 mg extract from A549 and MDA-MB231 cells. Proteins were diluted with IP buffer and IP was performed in the presence of 0Á5% Triton X-100 for 2 h at 4°C. After 3 washes with 0Á5% Triton X-100 IP buffer, EPOR protein was eluted by boiling in Laemmli sample buffer (pH 6Á8) for 5 min, loaded on a SDS-polyacrylamide gel and analysed by Western blot using GM1201 antibody.
Mass spectrometry -Nano-high performance liquid chromatography -MS/MS Four milligram of UT-7 cell extract was immunoprecipitated with GM1202 and GM1203 (see Table II ) agarose-coupled antibodies (mixture of 1:1, 6 lg antibodies each). After extensive washing, the precipitated proteins were separated by a 10% SDS-polyacrylamide gel electophoresis and visualized with Coomassie Blue. Protein digests of the gel piece covering the 65 kD region were analysed using an UltiMate 3000 nano-HPLC system (Dionex, Germering, Germany) coupled to an LTQ Orbitrap XL mass spectrometer. An in-house fritless fused-silica microcapillary column (75 lm i.d., 280 lm o.d.) packed with 10 cm of 3-lm reversed-phase C18 material (Reprosil, Dr Maish GmbH, Ammerbuch-Entringen, Germany) was used. The gradient (solvent A, 0Á1% formic acid; solvent B, 0Á1% formic acid in 85% acetonitrile) started at 4% B. The concentration of solvent B was increased linearly from 4 to 50% over 50 min and from 50 to 100% over 5 min. A flow rate of 250 nl/min was applied. Data analysis was performed using Proteome Discoverer 1.3 (ThermoScientific) with search engine Sequest (http://fields.scripps.edu/sequest/). Precursor mass tolerance was set to 10 ppm, fragment mass tolerance was 0Á8 Da. Raw data obtained by liquid chromatography-electrospray ionization mass spectrometry (LC-ESI-MS) were searched against the Homo sapiens protein database extracted from the NCBInr database using false discovery rate (FDR) for peptide evaluation. Only peptides with a significance threshold of 0Á01 (99% confidence) or less were used for protein identification.
Immunohistochemistry
To test the suitability of antibodies for clinical applications in FFPE material, we used UT-7, REH and NALM-6 cell lines, as they have differential endogenous EPOR expression. They were grown to confluence in 29 T75 flasks, removed and fixed in 10% formal saline (BCS Biosciences Ltd, Cambridge, UK) overnight and processed to paraffin wax. Sections were prepared and stained by all antibodies at concentrations of 2-10 lg/ml following pressure cooking antigen retrieval, and using anti-rabbit/-mouse Envision (Dako, Cambridge, UK), or peroxidase-conjugated anti-rat immunoglobulin (Sigma-Aldrich, Gillingham, UK) localization. Sections were prepared from bone marrow samples and stained at 4 lg/ml concentration using automated IHC (Discovery XT; Roche Tissue Diagnostics, Burgess Hill, UK) and CC1 conditioning. Bone marrow aspirate smears and cultured erythroid progenitor cells were mounted on glass slides and fixed overnight in 95% methylated ethanol. After washing in water, slides were flooded with PBS pH 7Á0 and primary antibodies incubated overnight at 4°C (rat anti-EPOR GM1201 Aldevron, Freiburg, Germany) and rabbit anti-ferritin H (ab75972, 
Results
Monoclonal antibodies generated by genetic immunization against hEPOR-ECD Four murine and five rat mother hybridomas were preselected for their ability to recognize the hEPOR ECD constructs in flow cytometry. Purified monoclonal antibodies were tested by flow cytometry at 1 lg/ml (Fig 1A-C ).
Monoclonal antibody generation using synthetic peptides
Supernatants from the stable mother clones were pre-tested for the selection of the best mother clones for each assay (Western blots, IP, IHC, immunofluorescence and flow cytometry) with respect to signal strength and specificity. The chosen mother clones were then subcloned by serial dilution, expanded, isotyped and antibodies purified using protein G columns and resuspended in PBS to a given concentration (1-2 mg/ml). The results of the chosen subclones that revealed the most unequivocal results in the various assays were generated against human peptide 6, which is located close to the C-terminal region of EPOR (Table I) .
Systematic nomenclature of monoclonal antibodies
Of 15 monoclonal antibody mother clones, four were selected for subcloning and additional testing (Table II) . Depending on the antibody source, a goat anti-mouse IgG R-conjugate (#1030-09, Southern Biotech, Birmingham, AL, USA), or a goat anti-rat IgG R-PE conjugate (#3030, Southern Biotech) were used as secondary antibodies at 10 lg/ml. As negative control BOSC23 cells, transfected with an irrelevant control cDNA cloned into the corresponding expression vector, were incubated with each monoclonal antibody and detected with the secondary antibody described above (black curves). (C) Cells were incubated with primary antibodies (4 lg/ml for UT-7 cells; 10 lg/ml for A549 and MDA-MB-231 cells), followed by FITC-conjugated secondary antibodies (15 lg/ml). Black line: GM1202, GM1203 and GM1204; Red line: secondary antibody only. EPOR, erythropoietin receptor; EGFR, epithelial growth factor receptor. Flow cytometry analysis of EPOR The GM1202, GM1203 and GM1204 antibodies, raised against the ECD, recognized hEPOR by fluorescence-activated cell sorting (FACS) analysis, on Bosc23 cells transfected with HA tagged hEPOR or EGFR cDNA constructs. The three antibodies showed similar levels of hEPOR expression as compared to anti-HA antibody (positive control). Isotype controls (data not shown) and secondary antibodies were used as negative controls. The specificity of the antibodies was verified by the lack of reactivity in HA-EGFR transfected cells. Using FACS analysis, the same antibodies also detected endogenous hEPOR in UT-7, A549 and MDA-MB-231 cells. hEPOR was detected with higher sensitivity in UT-7 cells (4 lg/ml antibody concentration) than in A549 and MDA-MB-231 (10 lg/ml).
Immunofluorescence
COS7 cells were transfected with HA-hEPOR cDNA and stained with GM1202 and GM1203 directed against the ECD and GM1201 directed against the ICD (Fig 2A) using anti-HA as a positive control. The three antibodies detected hEPOR and specificity was verified using isotype controls (data not shown).
HEK293T cells were transfected with DNA encoding a fusion protein of ECFP and EPOR, incubated for 24 h and then stained with GM1201, directed against the ICD, and GM1202 or GM1203, directed against the ECD, of EPOR ( Fig 2B) . Colour coding was set to equal values for ECFP and Alexa555 (secondary antibody label) channels with the exception listed in the legend to Fig 2B. For the anti-EPOR antibodies GM1202 and GM1203 (rows 2 and 3), perfect co-localization at the membrane of immunofluorescence with ECFP fluorescence was observed, indicating specific recognition of EPOR protein by the antibodies. In contrast, the antibodies did not detect the ECFP-EGFR-EPOR fusion protein, which was sufficiently expressed (as can be seen in the ECFP channel) and therefore served as a negative control (upper row). GM1201 antibody was only able to detect EPOR protein in permeabilized cells, indicating correct orientation of the ECFP-EPOR fusion protein and supporting its specificity for the ICD of EPOR. Interestingly, this antibody also detects the ICD in a fusion protein made from ECFP, the ECD of EGFR and the ICD of EPOR. Reactivity of the GM1201, GM1202 and GM1203 antibodies with hEPOR was also demonstrated in UT-7, A549 and MDA-MB-231 cells, showing significantly higher sensitivity in UT-7 cells.
Endogenous EPOR expression in tumour cell lines
The ability of the antibodies to recognize endogenous EPOR expression in tumour cells was tested by immunofluorescence ( Fig 3) and Western blot analysis (Fig 4) using the UT-7 cell line as well as EPOR-silenced breast carcinoma MDA-MB-231 cells and EPOR-silenced lung carcinoma A549 cells (shE-POR) and the corresponding control cells (shSCR). RNA analysis in these cells showed that the EPOR mRNA level in UT-7 is 270 AE 8 times higher than in MDA-MB-231 control cells (MDA-MB-231-shSCR) and 56 AE 2 times higher than in A549 control cells (A549-shSCR). Further RNA analysis in EPOR-silenced MDA-MB-231 and A549 cells showed that EPOR mRNA expression declined by 82 AE 3% and 70 AE 3% respectively, which validated these cellular models for testing GM1201 antibody by Western blot. In line with these RNA data, Western blotting showed a main signal around 63 kDa in these three cell lines and was negative for EPOR-silenced cells (Fig 4) . This signal was much higher in UT-7 than in MDA-MB-231 and A549 control cells, reflecting that Western blot signal parallels EPOR mRNA levels in these cells. Moreover, GM1201 has the potential to detect higher molecular weight EPOR forms, which are much weaker than the main 63 kDa form. Collectively, these data indicate that GM1201 reliably detects endogenous EPOR by Western blotting.
Identification of antibodies that specifically immunoprecipitate overexpressed and endogenous human EPOR
Using overexpressed HA-hEPOR as a source, GM1201, GM1202 and GM1203, were identified as antibodies with the highest immunoprecipitating efficiency ( Fig 5A) . Of note, the rat-derived antibody GM1201 was as efficient as the commercial anti-HA-tag antibody by IP ( Fig 5A) . The GM1201 antibody was also used to detect untagged immunoprecipitated hEPOR in Western blots. Besides this antibody, two mouse-derived antibodies directed against the ECD of EPOR, GM1202 and GM1203, were able to efficiently recover endogenous hEPOR in immunoprecipitates from UT-7, A569 and MDA-MB-231 cells (Fig 5B-D) . In the case of very low endogenous hEPOR expression in A549 or MDA-MB-231 cells, the use of these mouse antibodies prevented the detection of cross-reacting bands, which were precipitated if the same antibody (GM1201) was used in IP and Western blot [A549: Fig 5C (*) ; MDA-MB-231: data not shown].
In all cases and with all antibodies, IP was able to significantly enrich the EPOR compared to the cell lysate (10% of the IP input). Specificity of the immunoprecipitated bands was confirmed by knockdown of EPOR using shRNAs in A549 cells and MDA-MB-231 cells (Fig 5C, D) . The recovery of hEPOR in immunoprecipitates using GM1202 and GM1203 antibodies was further confirmed by Nano-HPLC-MS/MS, where seven EPOR-specific peptides were identified in trypsin-digested samples (Fig 6) . Together, these data revealed a specific and highly efficient hEPOR immunoprecipitating capacity of GM1201, GM1202 and GM1203.
Immunohistochemistry
Differential expression of EPOR mRNA expression was confirmed in NALM-6, REH and UT-7 cell lines by Q-PCR ( Fig 7A) . The rat antibody GM1201 showed strong staining in UT-7 cells and differential immunoreactivity between FFPE REH (relatively high endogenous EPOR) and FFPE NALM-6 (relatively low EPOR), see Fig 7B, C. On high magnification, this was seen to be cytoplasmic in distribution.
GM1201 was tested on FFPE non-erythroid cells, nonsmall cell lung carcinoma A549 and breast cancer MDA-MB-231 cell lines as knockdown models where lentiviral particles generated from three independent shEPOR sequences were used to infect MDA-MB-231 and A549 cells. A decline in EPOR protein was observed. Specificity of the antibodies towards EPOR in these two latter cell lines was ensured by the lack of immunoreactivity with the corresponding EPOR-silenced cells. High magnification confirmed reduced cytoplasmic immunoreactivity of shEpoR cells compared with those derived from cells treated with scrambled sequences (Fig 7D, E) . Summary results for GM1201 immunoreactivity, compared with GM1202, GM1203 and GM1204 are presented in Table III .
Immunoreactivity was found in erythroid cells in erythroblastic islands using the rat antibody GM1201, while metamyelocyte and neutrophil band forms were negative ( Fig 7F) . Immunoreactivity was also observed in cultured erythroid progenitor cells ( Fig 7G) and bone marrow aspirate ( Fig 7H) . Furthermore, GM1201 immunoreactivity co-localized with the erythroid differentiation antigens ferritin H and glycophorin C (Fig 7G, H) .
GM1201
GM1202 GM1203 ANTI-HA (A) (B) Fig 2. Immunofluorescence of transiently transfected hEPOR. (A) Cos7 cells were seeded on glass coverslips and transfected with HA-tagged hEPOR cDNA. Primary antibodies (and isotype matched controlsdata not shown) were used at a 7 lg/ml, and secondary antibodiesat 4 lg/ml. Nuclei were stained with DAPI. Confocal fluorescent images were obtained with a LEICA TCS SP5 II confocal microscope with 63x/1.4NA objective. (B) HEK293T cells were transfected with plasmids encoding the indicated fusion proteins and hEPOR for 24 h, and stained with GM1201 (intracytoplasmic domain; ICD) and GM1202 or GM1203 (extracellular domain; ECD). Colour coding is set to equal values for ECFP and Alexa555 channels except for the following recording: antibody GM1201 in ECFP-EGFR-EPOR transfected cells (antibody channel 8x less sensitive). All antibodies show perfect co-localization with the EPOR-ECFP (enhanced cyan fluorescent protein) chimaeras. Staining disappears when the ECD and the transmembrane domain of EPOR are substituted by that of EGFR except for the GM1201 antibody that has its epitope in the ICD. Localization differences are mostly due to different epitopes of the respective antibodies (GM1201: ICD vs.GM1202 and GM1203: ECD). Confocal fluorescent images were obtained by a Zeiss Axiovert 200M microscope equipped with a CSU10 spinning disc (Yokogawa, Tokyo, Japan) and a 100x/1.3NA oil immersion objective. EPOR, erythropoietin receptor; EGFR, epithelial growth factor receptor; ECFP, enhanced cyan fluorescent protein. Detection of endogenous hEPOR by immunofluorescence. UT-7 cells were collected and fixed in 3% paraformaldehyde in phosphate-buffered saline at room temperature (RT) for 30 min. Primary antibodies (and isotype controlsnot shown) were diluted to 4 lg/ml in quenching buffer. Secondary antibodies [fluorescein isothiocyanate (FITC)-conjugated AffinityPure Goat Anti-Mouse IgG for GM1202 and GM1203 antibodies and FITC-conjugated AffinityPure Goat Anti-Rat IgG for the GM1201 antibody] were diluted to 4 lg/ml. MDA-MB-231 and A549 cells were seeded on glass coverslips. Primary antibodies (and Isotype controlsnot shown) were diluted to 20 lg/ml and secondary antibodies were used at 7Á5 lg/ml. Nuclei were stained with DRAQ5 (2Á5 lmol/l) for 30 min at RT. Confocal fluorescent images were obtained by a LEICA TCS SP5 II confocal microscope with a 63x objective.
Discussion
A spectrum of strongly held views concerning EPOR function in tumours is evident in the literature, ranging from claims that malignant cells are devoid of functional EPORmediated signalling pathways to assertions that there is an overlap of cell signalling pathways that has pathogenic significance (Ghezzi et al, 2010) .
Previous immunohistochemical studies on tumour tissue have drawn controversial conclusions about the expression of EPOR, based on antibodies that were later shown to crossreact with other cellular proteins (Elliott et al, 2006; Brown et al, 2007) . The ideal antibody for IHC would be monoclonal rather than polyclonal, possess immunoreactivity against a defined EPOR domain and lack cross-reactivity with other tissue constituents. Unfortunately, most studies reported to date have used polyclonal antibodies or monoclonal antibodies of undefined specificity. Undoubtedly, the resulting discrepancies have masked the important debate about the safety of treating anaemic cancer patients with rHuEPO. Two other related factors that have received scant consideration are the occurrence of EPOR splice variants (Arcasoy et al, 2003) and the possible involvement of a heterodimeric form of the receptor comprising one EPOR and one common b chain component (Broxmeyer, 2013) . Whereas homodimeric EPOR has been extensively studied, the existence of the heterodimeric complex is debated and requires further study.
The aim of the EpoCan consortium is to produce, characterize and validate a panel of EPOR monoclonal antibodies that would be readily available to the research community. These include antibodies raised against the ECD of EPOR for FACS analysis; those that recognize the denatured EPOR (F) Immunohistochemical staining of bone marrow for EPOR. Bone marrow aspirate from a patient with polycythaemia vera stained with rat anti-EPOR (GM1201). Red arrow denotes an erythroblastic island consisting of a central macrophage surrounded by erythroblasts (brown staining). Nuclei were counterstained with haematoxylin (blue). Green arrows denote metamyelocytes and neutrophil band forms, which are clearly negative for EPOR staining. Final magnification 9750. (G) Immunohistochemical dual staining of erythroid progenitor cells. To illustrate erythroblast differentiation, cryopreserved bone marrow mononuclear cells were cultured for 14 d in MethoCult TM H4034 Optimum and dual stained with rat anti-EPOR (GM1201) and either rabbit anti-ferritin H or rabbit anti-glycophorin C. Co-immunoreactivity of EPOR (a, green) and ferritin heavy chain (b, red) is evident during erythroid differentiation (c, merge). EPOR is expressed more prominently in an early erythroblast (green; d and f) and to a lesser degree in later stages as demonstrated by cells with glycophorin C expression (red; e and f). Nuclei were counterstained with DAPI (blue and/or potential EPOR isoforms by Western blot; and those that would be useful for IHC studies of clinical specimens.
In the current study, peptide immunization was used to generate antibodies for assays on denatured proteins, such as Western blotting and IHC, whereas novel genetic immunization protocols were used to generate antibodies that recognize EPOR in its native conformation for flow cytometry, immunofluorescence and IP assays. In total, 15 monoclonal antibody mother clones, were pretested in different assays for human EPOR. They comprised six rat monoclonal antibodies generated by immunization of synthetic peptides based on the cytoplasmic domain of the hEPOR, as well as four murine and five rat monoclonal antibodies generated against the hEPOR ECD domain by genetic immunization.
The specificity of the EPOR antibodies has been validated by the use of EPOR-silenced cells. For example, we show that an endogenous Western blot signal using the GM1201 antibody is specifically down-regulated in EPOR-silenced cells, strongly indicating that this antibody recognizes endogenous EPOR in these cells. Although the GM1201 antibody may also detect non-specific signals in the A549 cell line (Fig 3) the EPOR-silenced cells clearly permit discrimination between a true EPOR-dependent signal and the non-specific signal. The number of monoclonal antibodies was reduced to a panel of four for Western blotting, IHC, IP, immunofluorescence and flow cytometry.
For simplicity, the monoclonal antibodies have been systematically named, based on an in-house nomenclature system at Aldevron Freiburg (see Table I ). GM1201 is a rat monoclonal antibody raised against one of six synthetic peptides used to immunize rats, which is located in the cytoplasmic domain of hEPOR (Table I) . This antibody reveals specific down-regulation of EPOR in EPOR-silenced MDA-MB-231 and A549 cells, confirming that it also recognizes endogenous EPOR in these cells. Importantly, GM1201 was sensitive and specific in immunohistochemical studies of both cultured erythroid cells and bone marrow aspirates. For example using FFPE sections of bone marrow and bone marrow aspirates, it was possible to visualize erythroblastic islands in a patient with polycythaemia vera, and to demonstrate co-localization of EPOR with either ferritin H or glycophorin C in differentiating erythroid progenitors in a patient with erythroid hyperplasia.
GM1202 and GM1203 are mouse monoclonal antibodies, raised by genetic immunization against the ECD of hEPOR. By co-localization of an ECFP-tagged EPOR and the signal obtained with our new antibodies GM1202 and GM1203 we show that GM1202 and GM1203 detect EPOR when it is expressed on the membrane (Fig 4) . Furthermore, GM1202 and GM1203 have proved useful in immunopreciptation experiments in combination with GM1201 (Fig 7) . GM1204 is a rat monoclonal antibody raised by genetic immunization of the ECD of hEPOR which detects both human and murine EPOR by FACS (mouse data not shown).
In a thorough, often overlooked study, Arcasoy et al (2003) isolated and characterized several novel cDNAs for EPOR splice variants expressed in cancer cells. Predicted amino acid sequences of these cDNAs indicated splice variants encoding soluble EPOR, variants containing insertions from intron 6 or intron 7, and membrane-bound EPOR peptides with intracytoplasmic truncations. These multiple EPOR isoforms in human cancer cells may modulate the cellular effects of recombinant EPO. Recently, Elliott et al (2013) reported on differences in detection of EPOR in primary human tumour tissue samples using different antibodies. Using an anti-hEPOR monoclonal antibody, they could not detect EPOR protein in normal human and matching cancer tissues from breast, lung, colon, ovary or skin. Detection of EPOR in breast cancer tissues using a polyclonal antibody was interpreted as cross-reactivity. However, it cannot currently be ruled out that the epitope recognized by the specific monoclonal antibody could be missing in EPOR isoforms found in tumour tissues.
The availability of monoclonal antibodies directed against specific exons, as those described herein, will enable, for the first time, the investigation of the resulting EPOR protein isoforms in different tissues. Thus, one antibody may recognize an epitope common to many EPOR isoforms, indicating a broader EPOR expression pattern compared to other antibodies whose epitope might only be present in fewer EPOR isoforms, with a more limited expression pattern.
The new antibodies will enable many interesting topics in EPOR biology to be explored. These include resolution of the major clinical question of which patients can be treated safely with EPO and its derivatives, dissection of the signalling mechanisms in non-erythroid cells and investigation of cancer cell:stromal cell interactions in tumours.
